- Thursday, April 4, 2024
6:15 AM – 7:30 AM ET
5K Fun Run
6:15 AM – 7:30 AM ET
5K Run for Cancer Research
7:00 AM – 8:00 AM ET
Non-CE Symposium: Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple Myeloma
7:00 AM – 8:00 AM ET
Non-CE Symposium: Key Considerations for Operationalizing Bispecifics in Relapsed or Refractory Multiple MyelomaLocation: 120-121*Speaker: – Minnesota Oncology
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC – Minnesota Oncology ### 894762###*Speaker###Director of Pharmacy###Minnesota Oncology###*Speaker: – Minnesota Oncology
### 7:00 AM – 8:00 AM ET
Non-CE Symposium: Essentials for Pharmacists: A Treatment Option for Relapsed or Refractory Multiple Myeloma From Pfizer
7:00 AM – 8:00 AM ET
Non-CE Symposium: Essentials for Pharmacists: A Treatment Option for Relapsed or Refractory Multiple Myeloma From PfizerLocation: 124-125*Speaker: – USC Norris Comprehensive Cancer Center
Amir Ali, PharmD – USC Norris Comprehensive Cancer Center ### 1252116###*Speaker###PGY-2 Oncology Resident###USC Norris Comprehensive Cancer Center###*Speaker: – USC Norris Comprehensive Cancer Center
### 7:00 AM – 8:00 AM ET
Non-CE Symposium: Managing Myelofibrosis: A Pharmacist’s Perspective
7:00 AM – 8:00 AM ET
Non-CE Symposium: Managing Myelofibrosis: A Pharmacist’s PerspectiveLocation: 122-123*Speaker: – The Mount Sinai Hospital
Kyle Farina, PharmD, BCPS, BCOP – The Mount Sinai Hospital ### 2251097###*Speaker######The Mount Sinai Hospital###*Speaker: – The Mount Sinai Hospital
### 7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Geriatric
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Geriatric
Location: 116
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - New Practitioner
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - New Practitioner
Location: 114
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Pediatrics
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Pediatrics
Location: 117
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Precision Health in Oncology
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Precision Health in OncologyLocation: 113
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Transplant & Cellular Therapy
7:00 AM – 8:00 AM ET
Special Interest Group (SIG) - Transplant & Cellular Therapy
Location: 115
8:15 AM – 9:30 AM ET
CAR T-Cell Breakthroughs in Lymphoma and Myeloma: Balancing Efficacy and Safety
8:15 AM – 9:30 AM ET
BC2 - CAR T-Cell Breakthroughs in Lymphoma and Myeloma: Balancing Efficacy and SafetyLocation: Ballroom B-CSpeaker: – The University of Texas MD Anderson Cancer Center
Brian Primeaux, PharmD, BCOP (he/him/his) – The University of Texas MD Anderson Cancer Center ### 1774213###Speaker###Clinical Pharmacy Specialist, Lymphoma/Myeloma/CAR-T###The University of Texas MD Anderson Cancer Center###Speaker: – The University of Texas MD Anderson Cancer Center
### he/him/his
8:15 AM – 9:30 AM ET
Moving Beyond One Size Fits All for Solid Tumors: Updates in Biomarker Driven Therapies
8:15 AM – 9:30 AM ET
201 - Moving Beyond One Size Fits All for Solid Tumors: Updates in Biomarker Driven Therapies Location: Ballroom ACo-Speaker: – Memorial Sloan Kettering Cancer Center
Co-Speaker: – Memorial Sloan Kettering Cancer Center
Raymond DeMatteo, PharmD, BCOP – Memorial Sloan Kettering Cancer Center ### 947774###Co-Speaker###Clinical Pharmacy Specialist###Memorial Sloan Kettering Cancer Center###Co-Speaker: – Memorial Sloan Kettering Cancer Center
### @@@ Adam Kahleifeh, PharmD, BCOP – Memorial Sloan Kettering Cancer Center ### 1252155###Co-Speaker###Clinical Pharmacy Specialist###Memorial Sloan Kettering Cancer Center###Co-Speaker: – Memorial Sloan Kettering Cancer Center
###
9:40 AM – 10:40 AM ET
1 - To Transplant or Not to Transplant: Current Treatment Approaches for Mantle Cell Lymphoma
9:40 AM – 10:40 AM ET
202-A - To Transplant or Not to Transplant: Current Treatment Approaches for Mantle Cell LymphomaLocation: Ballroom ASpeaker: – University of Illinois Chicago
Michael Buege, PharmD, BCOP – University of Illinois Chicago ### 2127671###Speaker###Clinical Assistant Professor###University of Illinois Chicago###Speaker: – University of Illinois Chicago
###
9:40 AM – 10:40 AM ET
2 - Baby Steps: Updates in the Treatment of Infant Leukemia
9:40 AM – 10:40 AM ET
202-B - Baby Steps: Updates in the Treatment of Infant LeukemiaLocation: Ballroom A
Catherine Martin, PharmD, BCOP (she/her/hers) – Mayo Clinic ### 1808423###Speaker###Pediatric Hematology/Oncology Ambulatory Care Pharmacist###Mayo Clinic###Speaker: – Mayo Clinic
### she/her/hers
9:40 AM – 10:40 AM ET
3 - Advances in Targeted Therapies for Gastrointestinal Malignancies
9:40 AM – 10:40 AM ET
203-A - Advances in Targeted Therapies for Gastrointestinal MalignanciesLocation: Ballroom DSpeaker: – Moffitt Cancer Center
Sarah Chehab, PharmD, BCOP (she/her/hers) – Moffitt Cancer Center ### 2127678###Speaker###Clinical Pharmacy Specialist- Medical Oncology###Moffitt Cancer Center###Speaker: – Moffitt Cancer Center
### she/her/hers
9:40 AM – 10:40 AM ET
4 - Targeting HER2 Alterations in Patients With Non-Breast/Non-Gastric Cancers
9:40 AM – 10:40 AM ET
203-B - Targeting HER2 Alterations in Patients With Non-Breast/Non-Gastric CancersLocation: Ballroom DSpeaker: – Memorial Sloan Kettering Cancer Center
Dazhi Liu, PharmD, BCOP – Memorial Sloan Kettering Cancer Center ### 2127675###Speaker###Clinical Pharmacy Specialist###Memorial Sloan Kettering Cancer Center###Speaker: – Memorial Sloan Kettering Cancer Center
###
9:40 AM – 10:40 AM ET
5 - Show Me the Money: Optimizing the Electronic Medical Record (EMR) to Improve Biosimilar Utilization and Pharmacy Reimbursement
9:40 AM – 10:40 AM ET
204-A - Show Me the Money: Optimizing the Electronic Medical Record (EMR) to Improve Biosimilar Utilization and Pharmacy ReimbursementLocation: Ballroom B-CSpeaker: – The University of Kansas Health System
Nikki R. Ogle, PharmD, BCOP (she/her/hers) – The University of Kansas Health System ### 2127662###Speaker###Oncology Reimbursement Pharmacist, Team Lead###The University of Kansas Health System###Speaker: – The University of Kansas Health System
### she/her/hers
9:40 AM – 10:40 AM ET
6 - Cannabinoids and the Oncology Patient: Pearls for Pharmacists
9:40 AM – 10:40 AM ET
204-B - Cannabinoids and the Oncology Patient: Pearls for PharmacistsLocation: Ballroom B-C
Marie Parish, PharmD, BCOP, BCPS (she/her/hers) – Mayo Clinic ### 2127683###Speaker###Clinical Oncology Pharmacist###Mayo Clinic###Speaker: – Mayo Clinic
### she/her/hers
10:50 AM – 11:50 AM ET
Member Awards & Business Meeting
10:50 AM – 11:50 AM ET
Member Awards & Business MeetingLocation: Ballroom B-C*Speaker: – Atrium Health Wake Forest Baptist (WFB)
LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA – Atrium Health Wake Forest Baptist (WFB) ### 1311883###*Speaker###Clinical Specialist - Stem Cell Transplant and Cellular Therapy###Atrium Health Wake Forest Baptist (WFB)###*Speaker: – Atrium Health Wake Forest Baptist (WFB)
### 11:50 AM – 2:15 PM ET
Exhibit Hall and Lunch
11:50 AM – 2:15 PM ET
Exhibit Hall and Lunch
Location: Exhibit Hall
12:00 PM – 1:00 PM ET
CE Symposium: Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment Optimization
12:00 PM – 1:00 PM ET
CE Symposium: Advancements in Early-Stage Breast Cancer: The Role of Oncology Pharmacists in Treatment OptimizationLocation: 122-123Co-Speaker: – Allegheny Health Network
Co-Speaker: – UK HealthCare
Co-Speaker:
Danielle Roman, PharmD, BCOP (she/her/hers) – Allegheny Health Network ### 2127689###Co-Speaker###Manager, Oncology Clinical Pharmacy Services###Allegheny Health Network###Co-Speaker: – Allegheny Health Network
### she/her/hers @@@ Allison Butts, PharmD, BCOP – UK HealthCare ### 1491239###Co-Speaker###Clinical Coordinator-Medical Oncology; PGY2 Pharmacy Residency Program Director- Oncology###UK HealthCare###Co-Speaker: – UK HealthCare
### @@@ Julia Ziegengeist, PharmD, BCOP ### 2269371###Co-Speaker#########Co-Speaker:
### 12:00 PM – 1:00 PM ET
CE Symposium: Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist Expertise
12:00 PM – 1:00 PM ET
CE Symposium: Elevating Safety and Adherence in Chronic Myeloid Leukemia Through Oncology Pharmacist ExpertiseLocation: 120-121Co-Speaker: – NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
Co-Speaker: – Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
Co-Speaker:
Peter Campbell, PharmD, MBA, BCOP – NewYork-Presbyterian Hospital, Columbia University Irving Medical Center ### 1589099###Co-Speaker######NewYork-Presbyterian Hospital, Columbia University Irving Medical Center###Co-Speaker: – NewYork-Presbyterian Hospital, Columbia University Irving Medical Center
### @@@ Benyam Muluneh, Pharm.D., BCOP, CPP – Eshelman School of Pharmacy, University of North Carolina at Chapel Hill ### 1137104###Co-Speaker###Assistant Professor###Eshelman School of Pharmacy, University of North Carolina at Chapel Hill###Co-Speaker: – Eshelman School of Pharmacy, University of North Carolina at Chapel Hill
### @@@ Jordan Snyder, PharmD, BCOP ### 2262350###Co-Speaker#########Co-Speaker:
### 12:00 PM – 1:00 PM ET
CE Symposium: What’s New in NSCLC Therapies? Key Takeaways for Your Pharmacy Practice
12:00 PM – 1:00 PM ET
CE Symposium: What’s New in NSCLC Therapies? Key Takeaways for Your Pharmacy PracticeLocation: 124-125
Val Adams, PharmD FCCP BCOP ### 957909###*Speaker###Associate Professor, University of Kentucky######*Speaker:
### @@@ Whitney Lewis, PharmD, BCOP ### 2238585###*Speaker###Clinical Pharmacy Specialist, The University of Texas, MD Anderson Cancer Center######*Speaker:
### 12:00 PM – 1:00 PM ET
Leadership Development Roundtable: Career Ladders and Professional Development Plans
12:00 PM – 1:00 PM ET
Leadership Development Roundtable: Career Ladders and Professional Development Plans
Location: 118 - 119
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Academia
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Academia
Location: 114
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Administration
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Administration
Location: 115
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Epic (Beacon) Users
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Epic (Beacon) Users
Location: 116
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Gynecologic Oncology
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Gynecologic Oncology
Location: 117
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Specialty Pharmacy
12:00 PM – 1:00 PM ET
Special Interest Group (SIG) - Specialty Pharmacy
Location: 113
1:00 PM – 2:00 PM ET
Annual Advocacy Update
1:00 PM – 2:00 PM ET
Annual Advocacy UpdateLocation: Ballroom B-C*Speaker: – HOPA
*Speaker: – The Brooklyn Cancer Center
*Speaker: – CRD Associates
Brooke Boring, MPH, CPhT (she/her/hers) – HOPA ### 1518390###*Speaker###Senior Manager of Health Policy & Advocacy###HOPA###*Speaker: – HOPA
### she/her/hers @@@ Lilia Davenport, PharmD, BCPS, BCOP (she/her/hers) – The Brooklyn Cancer Center ### 1553029###*Speaker###Clinical Pharmacy Manager and Oncology Pharmacotherapy Specialist ###The Brooklyn Cancer Center ###*Speaker: – The Brooklyn Cancer Center
### she/her/hers @@@ Jeremy Scott, MA – CRD Associates ### 969263###*Speaker###Senior Vice President###CRD Associates###*Speaker: – CRD Associates
### 2:15 PM – 3:30 PM ET
Debating the Incorporation of Novel Therapies in Front-Line Acute Lymphoblastic Leukemia Treatment
2:15 PM – 3:30 PM ET
205 - Debating the Incorporation of Novel Therapies in Front-Line Acute Lymphoblastic Leukemia TreatmentLocation: Ballroom ASpeaker: – University of Utah Huntsman Cancer Institute
Co-Speaker: – University of Utah Huntsman Cancer Institute
Charlotte B. Wagner, PharmD, BCOP (she/her/hers) – University of Utah Huntsman Cancer Institute ### 2127679###Speaker###Clinical Pharmacist###University of Utah Huntsman Cancer Institute###Speaker: – University of Utah Huntsman Cancer Institute
### she/her/hers @@@ Taylor Kujawa, PharmD (she/her/hers) – University of Utah Huntsman Cancer Institute ### 2127680###Co-Speaker###Clinical Pharmacist###University of Utah Huntsman Cancer Institute###Co-Speaker: – University of Utah Huntsman Cancer Institute
### she/her/hers
2:15 PM – 3:30 PM ET
The Great Financial Debate: Cost vs Margin for Cancer Care Drugs
2:15 PM – 3:30 PM ET
BC3 - The Great Financial Debate: Cost vs Margin for Cancer Care DrugsLocation: Ballroom B-CCo-Speaker: – Mayo Clinic
Co-Speaker: – Mayo Clinic
Scott A. Soefje, PharmD, BCOP, FCCP, FHOPA, MBA (he/him/his) – Mayo Clinic ### 894791###Co-Speaker###Director, Pharmacy Cancer Care###Mayo Clinic###Co-Speaker: – Mayo Clinic
### he/him/his @@@ Chelsee J. Jensen, PharmD, BCPS, P-RCM (she/her/hers) – Mayo Clinic ### 2127682###Co-Speaker###Senior Pharmacy Specialist- Pharmaceutical Formulary Manager###Mayo Clinic###Co-Speaker: – Mayo Clinic
### she/her/hers
3:45 PM – 4:45 PM ET
New Practitioner’s Guide to Navigating Your Career
3:45 PM – 4:45 PM ET
206 - New Practitioner’s Guide to Navigating Your CareerLocation: Ballroom ACo-Speaker: – MD Anderson Cancer Center, Houston, TX
Co-Speaker: – Golisano Children's Hospital
Co-Speaker: – VCU Health System, Richmond VA
Co-Speaker: – UT MD Anderson Cancer Center
Alison M. Gulbis, PharmD, BCOP (she/her/hers) – MD Anderson Cancer Center, Houston, TX ### 1637191###Co-Speaker###Clinical Pharmacy Manager###MD Anderson Cancer Center, Houston, TX###Co-Speaker: – MD Anderson Cancer Center, Houston, TX
### she/her/hers @@@ Jordan Wallace, PharmD, BCOP, CPh (she/her/hers) – Golisano Children's Hospital ### 1553108###Co-Speaker###Pediatric Oncology Pharmacy Clinical Specialist###Golisano Children's Hospital###Co-Speaker: – Golisano Children's Hospital
### she/her/hers @@@ Matthew Peery, PharmD (he/him/his) – VCU Health System, Richmond VA ### 1897695###Co-Speaker###Oncology Clinical Pharmacy Specialist###VCU Health System, Richmond VA###Co-Speaker: – VCU Health System, Richmond VA
### he/him/his @@@ Emma Garrison, PharmD, BCOP – UT MD Anderson Cancer Center ### 2128386###Co-Speaker###Oncology Clinical Pharmacy Specialist###UT MD Anderson Cancer Center###Co-Speaker: – UT MD Anderson Cancer Center
###
3:45 PM – 4:45 PM ET
Nuances in Neuro-Oncology: Glioma Treatment Advances and New Diagnostic
3:45 PM – 4:45 PM ET
BC4 - Nuances in Neuro-Oncology: Glioma Treatment Advances and New Diagnostic Definitions ("BCOP 101" format)Location: Ballroom B-CSpeaker: – Huntsman Cancer Institute
Kelly A. Fritz, PharmD, BCOP (she/her/hers) – Huntsman Cancer Institute ### 2010623###Speaker###Clinical Coordinator###Huntsman Cancer Institute###Speaker: – Huntsman Cancer Institute
### she/her/hers
3:45 PM – 4:45 PM ET
REACHing for ROCKstars –iNTEGRATing Updates in Chronic Graft Versus Host Disease
3:45 PM – 4:45 PM ET
207 - REACHing for ROCKstars –iNTEGRATing Updates in Chronic Graft Versus Host DiseaseLocation: Ballroom DSpeaker: – Oregon Health and Sciences University
Shannon E. Palmer, PharmD, BCOP (she/her/hers) – Oregon Health and Sciences University ### 1252219###Speaker###Hematology and Bone Marrow Transplant Pharmacist###Oregon Health and Sciences University###Speaker: – Oregon Health and Sciences University
### she/her/hers
4:45 PM – 7:30 PM ET
Exhibit Hall Evening Reception
4:45 PM – 7:30 PM ET
Exhibit Hall Evening Reception
Location: Exhibit Hall
5:00 PM – 6:00 PM ET
Diversity + Belonging Reception
5:00 PM – 6:00 PM ET
Diversity + Belonging Reception
Location: 118 - 119
5:00 PM – 7:30 PM ET
E-Poster Presentations: Completed Research and Trainee Top Ten
5:00 PM – 7:30 PM ET
E-Poster Presentations: Completed Research and Trainee Top Ten
Location: Exhibit Hall
5:30 PM – 6:30 PM ET
Non-CE Symposium: Review of Evidence-Based Data for an Antibody-Drug Conjugate in Combination With a PD-1 Inhibitor for 1L la/mUC
5:30 PM – 6:30 PM ET
Non-CE Symposium: Review of Evidence-Based Data for an Antibody-Drug Conjugate in Combination With a PD-1 Inhibitor for 1L la/mUCLocation: 122-123
Sandra Cuellar, PharmD, BCOP, FHOPA, FASHP ### 957901###*Speaker#########*Speaker:
### 5:30 PM – 6:30 PM ET
Non-CE Symposium: EMERALD study update: Exploring the safety and efficacy data in patients with ER+/HER2, ESR1-mutated mBC, including data from subgroup analyses
5:30 PM – 6:30 PM ET
Non-CE Symposium: EMERALD study update: Exploring the safety and efficacy data in patients with ER+/HER2, ESR1-mutated mBC, including data from subgroup analysesLocation: 120-121*Speaker: – Menarini Stemline
Scott Ostriker, PharmD, MBA, BCOP – Menarini Stemline ### 2251099###*Speaker######Menarini Stemline###*Speaker: – Menarini Stemline
### 6:00 PM – 8:00 PM ET
IRC Reception (Invite Only)
6:00 PM – 8:00 PM ET
IRC Reception (Invite Only)
